NEW PEPTIDE-BASED CANCER VACCINE: PHASE I AND EARLY PHASE II CLINICAL TRIALS FOR CASTRATION-RESISTANT PROSTATE CANCER

被引：0
|
作者：
Noguchi, M. [1 ,2 ]
Suekane, S. [2 ]
Moriya, F. [2 ]
Sasada, T. [3 ]
Yamada, A. [3 ]
Itoh, K. [3 ]
机构：
[1] Kurume Univ, Sch Med, Res Ctr Innovat Canc Therapy, Div Clin Res, Kurume, Fukuoka 830, Japan
[2] Kurume Univ, Sch Med, Dept Urol, Kurume, Fukuoka 830, Japan
[3] Kurume Univ, Sch Med, Dept Immunol & Immunotherapy, Kurume, Fukuoka 830, Japan
来源：
ANNALS OF ONCOLOGY | 2012年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：74 / 74
页数：1
相关论文
共 50 条
  • [41] Multicenter phase II study of trabectedin in patients with metastatic castration-resistant prostate cancer
    Michaelson, M. D.
    Bellmunt, J.
    Hudes, G. R.
    Goel, S.
    Lee, R. J.
    Kantoff, P. W.
    Stein, C. A.
    Lardelli, P.
    Pardos, I.
    Kahatt, C.
    Nieto, A.
    Cullell-Young, M.
    Lewis, N. L.
    Smith, M. R.
    ANNALS OF ONCOLOGY, 2012, 23 (05) : 1234 - 1240
  • [42] Randomized phase II study of nintedanib in metastatic castration-resistant prostate cancer postdocetaxel
    Droz, Jean-Pierre
    Medioni, Jaques
    Chevreau, Christine
    De Mont-Serrat, Helene
    Merger, Michael
    Stopfer, Peter
    Kaiser, Rolf
    Oudard, Stephane
    ANTI-CANCER DRUGS, 2014, 25 (09) : 1081 - 1088
  • [43] A phase I/IIA study of AGS-PSCA for castration-resistant prostate cancer
    Morris, M. J.
    Eisenberger, M. A.
    Pili, R.
    Denmeade, S. R.
    Rathkopf, D.
    Slovin, S. F.
    Farrelly, J.
    Chudow, J. J.
    Vincent, M.
    Scher, H. I.
    Carducci, M. A.
    ANNALS OF ONCOLOGY, 2012, 23 (10) : 2714 - 2719
  • [44] A phase I study of niclosamide in combination with enzalutamide in men with castration-resistant prostate cancer
    Schweizer, Michael T.
    Haugk, Kathleen
    McKiernan, Jozefa S.
    Gulati, Roman
    Cheng, Heather H.
    Maes, Jessica L.
    Dumpit, Ruth F.
    Nelson, Peter S.
    Montgomery, Bruce
    McCune, Jeannine S.
    Plymate, Stephen R.
    Yu, Evan Y.
    PLOS ONE, 2018, 13 (06):
  • [45] Intermittent chemotherapy (ICh) for metastatic castration-resistant prostate cancer (mCRPC): Results of a prospective randomized phase II trial of the DoD Prostate Cancer Clinical Trials Consortium
    Harzstark, A. L.
    Beer, T. M.
    Weinberg, V. K.
    Higano, C. S.
    Nordquist, L. T.
    Rosenberg, J. E.
    Alumkal, J. J.
    Yu, E. Y.
    Mi, J.
    Small, E. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (07)
  • [46] Ixabepilone, mitoxantrone, and prednisone in patients with metastatic castration-resistant prostate cancer refractory to docetaxel-based therapy: A phase II study of the DOD Prostate Cancer Clinical Trials Consortium
    Small, E.
    Harzstark, A.
    Weinberg, V. K.
    Smith, D. C.
    Mathew, P.
    Beer, T.
    Liu, G.
    Sharib, J.
    Rosenberg, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [47] Antitumor activity of MDV3100 in a phase I/II study of castration-resistant prostate cancer (CRPC)
    Scher, H. I.
    Beer, T. M.
    Higano, C. S.
    Taplin, M.
    Efstathiou, E.
    Anand, A.
    Hung, D.
    Hirmand, M.
    Fleisher, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [48] A phase I/II study of docetaxel in combination with pegylated liposomal doxorubicin in metastatic castration-resistant prostate cancer
    Laber, Damian A.
    Eatrides, Jennifer
    Jaglal, Michael V.
    Haider, Mintallah
    Visweshwar, Nathan
    Patel, Ankita
    MEDICAL ONCOLOGY, 2020, 37 (10)
  • [49] A phase 2 clinical trial of everolimus plus bicalutamide for castration-resistant prostate cancer
    Chow, Helen
    Ghosh, Paramita M.
    White, Ralph deVere
    Evans, Christopher P.
    Dall'Era, Marc A.
    Yap, Stanley A.
    Li, Yueju
    Beckett, Laurel A.
    Lara, Primo N.
    Pan, Chong-Xian
    CANCER, 2016, 122 (12) : 1897 - 1904
  • [50] Phase I/II study of the androgen receptor antagonist MDV3100 in castration-resistant prostate cancer
    Scher, Howard I.
    Beer, Thomasz
    Higano, Celestia S.
    Danila, Daniel C.
    Shelkey, Julia
    Hirmand, Mohammed
    Hung, David
    Morris, Michael J.
    Larson, Steve M.
    Sawyers, Charles L.
    CANCER RESEARCH, 2008, 68 (09)
12345